Bringing the Malaysian healthcare industry to greater heights: Provepharm and Pharm-D join forces to provide “Proveblue® 5 mg/ml solution for injection” in Malaysia


Provepharm, an international, private and sustainable pharmaceutical company specialized in revitalizing molecules and Pharm-D, a healthcare and pharmaceutical company based in Malaysia with a strong foothold in Singapore, announce today their partnership to launch Proveblue® 5 mg/ml solution for injection in Malaysia. Proveblue® is, a methylthioninium chloride product compliant with European Pharmacopeia standards.


Proveblue® 5 mg/ml solution for injection is indicated in Malaysia for the treatment of drug and chemical products-induced methaemoglobinaemia, as a dye in diagnostic procedures such as fistula detection and for the delineation of certain body tissues during surgery.


Marketing authorization of Proveblue® 5mg/ml, solution for injection was granted by the Malaysian authorities in January 2023. It is the only methylthioninium chloride product registered in Malaysia.


Under this agreement, Pharm-D is responsible for all commercial activities relating to the Product in Malaysia.


"We are pleased to be collaborating with Pharm-d which has such a good understanding of the antidotes and dye market in Malaysia. Moreover, we are pleased to work together to make Proveblue® 5 mg/ml solution for injection available for Malaysian patients." says Michel Feraud, CEO and founder of Provepharm.


"We are delighted to be collaborating with Provepharm with whom we share similar values and goals. This collaboration is in line with Pharm-D’s mission to launch and provide products that respond to medical and patient needs of Malaysia,says Mr. Lim Kean Ping, CEO of Pharm-D.


Press Release >

You are about to leave the Provepharm Corporate website. If you continue you will reach the website of our US subsidiary which the information is not necessarily applicable to France.